publication venue for
- Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.. 21. 2024
- The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer.. 19. 2022
- Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.. 19. 2022
- Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance.. 17. 2020
- Interval breast cancers - insights into a complex phenotype.. 17. 2020
- Use of genomics to balance cure and complications.. 17. 2020
- Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.. 16. 2019
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.. 15. 2017
- Correction regarding data on blinatumomab-associated seizures.. 13. 2016
- Gastric cancer drug trials - are women second class citizens?. 11. 2014
- Sarcoma: primary retroperitoneal sarcoma-predicting survival.. 10. 2013
- Multidisciplinary management of meningiomas in the era of precision oncology. 2026
- Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. 2024
- Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients. 2024
- BRAF - a tumour-agnostic drug target with lineage-specific dependencies. 2024
- Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. 2024
- Emerging evidence for adapting radiotherapy to immunotherapy. 2023
- Improving outcomes in patients with oesophageal cancer. 2023
- Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. 2022
- Clinical implications of T cell exhaustion for cancer immunotherapy. 2022
- Is early-onset cancer an emerging global epidemic? Current evidence and future implications. 2022
- Radiotheranostics in oncology: current challenges and emerging opportunities. 2022
- Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. 2021
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. 2021
- Immunogenicity of CAR T cells in cancer therapy. 2021
- Unlocking the potential of antibody-drug conjugates for cancer therapy. 2021
- ROS1-dependent cancers - biology, diagnostics and therapeutics. 2020
- MET-dependent solid tumours - molecular diagnosis and targeted therapy. 2020
- Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy. 2020
- Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy. 2019
- Towards individualized therapy for metastatic renal cell carcinoma. 2019
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. 2019
- Challenges to curing primary brain tumours. 2019
- Emerging epigenetic-modulating therapies in lymphoma. 2019
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. 2019
- Accelerating anticancer drug development - opportunities and trade-offs. 2018
- NTRK fusion-positive cancers and TRK inhibitor therapy. 2018
- Treatment resistance in urothelial carcinoma: an evolutionary perspective. 2018
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. 2017
- Drug development for noncastrate prostate cancer in a changed therapeutic landscape. 2017
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. 2017
- Unravelling the biology of SCLC: implications for therapy. 2017
- Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. 2017
- The high price of anticancer drugs: origins, implications, barriers, solutions. 2017
- Small-cell lung cancer in 2016: Shining light on novel targets and therapies. 2016
- Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. 2016
- Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. 2016
- Imaging biomarker roadmap for cancer studies. 2016
- Genomic complexity of multiple myeloma and its clinical implications. 2016
- Non-invasive metabolic imaging of brain tumours in the era of precision medicine. 2016
- Counselling framework for moderate-penetrance cancer-susceptibility mutations. 2016
- Population-based screening for cancer: hope and hype. 2016
- Clinical impact of tumour biology in the management of gastroesophageal cancer. 2016
- Drug therapy: Preclinical oncology - reporting transparency needed. 2015
- Molecular therapy for acute myeloid leukaemia. 2015
- Cancer-treatment-induced neurotoxicity--focus on newer treatments. 2015
- Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. 2015
- Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. 2015
- Current management of lesions associated with an increased risk of breast cancer. 2015
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside. 2015
- Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress. 2014
- Decade in review--genomics: a decade of discovery in cancer genomics. 2014
- Precision therapy for lymphoma--current state and future directions. 2014
- High-risk prostate cancer-classification and therapy. 2014
- Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. 2013
- Molecular targets on the horizon for kidney and urothelial cancer. 2013
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. 2013
- Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. 2013
- The future of epigenetic therapy in solid tumours--lessons from the past. 2013
- Validation and clinical utility of prostate cancer biomarkers. 2013
- Reducing the toxicity of cancer therapy: recognizing needs, taking action. 2012
- Noninvasive cell-tracking methods. 2011
- Chemotherapy: Standardizing the care of invasive bladder cancer. 2011
- The role of local therapy in the management of lung and liver oligometastases. 2011
- Metastasis-suppressor genes in clinical practice: lost in translation? 2011
- Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled? 2011
- Molecular mechanisms of metastasis in breast cancer--clinical applications. 2010
- 200 mg/m(2) melphalan--the gold standard for multiple myeloma. 2010
- Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. 2010
- Stereotactic body radiation therapy: a novel treatment modality. 2009
- Apples and oranges: the low and mid versus the upper rectum. 2009
- Molecular targets for treatment of inflammatory breast cancer. 2009
- Prostate cancer in 2011: Hitting old targets better and identifying new targets. 2012